Kangtai Biologics shareholders approve all resolutions at AGM

Shenzhen Kangtai Biological Products (SZSE:300601) announced the successful passage of all resolutions at its 2024 Annual General Meeting (AGM) held on May 20, 2025. Key resolutions included the approval of the 2024 Board of Directors' Work Report, the 2024 Supervisory Board Work Report, and the company's 2024 financial statements. Shareholders also approved the proposed 2024 profit distribution plan and the reappointment of the accounting firm for the 2025 fiscal year. The AGM saw participation from shareholders representing 47.3793% of the company's total shares. All resolutions received overwhelming support, with approval rates exceeding 99% of the votes cast.